Schizophrenia. Schizophrenia
Conditions
Interventions
Intervention 1: Haloperidol, 20 mg/day, orally, plus Ascorbic acid, 1500 mg/day, for 6 weeks, Biperiden (up to 6 mg/day) and lorazepam tablets were available for extra-pyramidal side effects and agita
Treatment - Drugs
Haloperidol, 20 mg/day, orally, plus Ascorbic acid, 1500 mg/day, for 6 weeks, Biperiden (up to 6 mg/day) and lorazepam tablets were available for extra-pyramidal side effects and agitation or anxiety
Haloperidol, 20 mg/day, orally, plus Placebo, for 6 weeks, Biperiden (up to 6 mg/day) and lorazepam tablets were available for extra-pyramidal side effects and agitation or anxiety respectively
Sponsors
Mazandaran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: DSM-IV-TR criteria for schizophrenia, Informed consent of the patients and their tutor, living in the southern coastwise of the Caspian sea, Hospitalization in Zare Hospital Exclusion criteria: Treatment resistance schizophrenia
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Symptoms of schizophrenia. Timepoint: weekly. Method of measurement: Brief Psychiatric Rating Scale (BPRS). | — |
Secondary
| Measure | Time frame |
|---|---|
| Faster response to haloperidol and side effects. Timepoint: weekly. Method of measurement: Brief Psychiatric Rating Scale (BPRS) and clinical interview and examination. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMehran Zarghami
Mazandaran University of Medical Sciences
Outcome results
None listed